The homo-pentameric α7 nicotinic acetylcholine receptor is an important target in design of selective drugs for disorders involving this prevalent receptor family. Results: α7/Ac-AChBP structured chimeric protein resembles binding characteristics of native receptor. Conclusion: Soluble mutant templates can be used in the design of novel α7 selective drugs Significance: Crystallographic structures of surrogates can guide therapeutic development for nicotinic acetylcholine receptor ligands.
SUMMARY
Determining the structure of the ligand binding domain of the nicotinic acetylcholine receptor (nAChR) has been a long standing goal in the design of selective drugs useful in implicated diseases for this prevalent receptor family. Acetylcholine binding proteins have proven to be useful surrogates with structural similarity and sequence identity to the extracellular domain of the nicotinic receptor. Yet these soluble proteins have their unique features and do not serve as exact replicates of the nAChRs of interest. Here we systematically modify the sequence of these proteins towards the homomeric human alpha-7 nAChR. These chimeric proteins exhibit a shift in affinities to reflect alpha-7 binding characteristics, yet maintain expression levels and stability conducive for crystallization. We also present a pentameric humanoid nAChR extracellular domain with the structural determination of the alpha-7 nAChR glycosylation site.
The pentameric Cys-loop ligand-gated ion channels are a dominant functioning target for rapid control of tissue excitability by neurotransmitters. Within this large family, nicotinic receptors have received the greatest attention in structural characterization and in definition of the ligand binding site (1) (2) (3) . Structural determination of the extracellular domain of a human alpha-7 nicotinic acetylcholine receptor (nAChR) provides a potential framework for structure-guided drug design for disorders in which the nicotinic receptor family has been implicated (1, 2) . Using mutagenesis and affinity labeling, nonneighboring residues in the primary sequence of the protein were identified as important in ligand binding (4) (5) (6) (7) (8) . Several studies have shown expression of alpha-7 nAChR extracellular domains (9) (10) (11) or variants (12) (13) (14) , yet none have resulted in crystal structures. Studies involving the Lymnaea stagnalis (Ls) and Aplysia californica (Ac) acetylcholine binding proteins (AChBP) have yielded many structural analyses of the binding site for these mollusk homologues (15) (16) (17) (18) (19) (20) (21) .
Recently determined structures of multiple ligand complexes with the Ac-AChBP (18, 19) , along with binding and mutagenesis studies have begun to define the structural determinants of ligand specificity (4, 8) . Here we develop a systematic study converting the Ls and Ac nAChR extracellular domain homologues specifically in the ligand cells (22) are maintained in Dulbecco's Modified Eagle's Medium (Mediatech) with 10% fetal bovine serum (Gemini Bio-Products; Atlanta Biologicals), 1% d-glutamine (Invitrogen) at 37°C and 10% CO 2 . After verification by sequencing, cDNAs were transfected via calcium phosphate by mixing (listed at final concentrations) 1x HEPES buffer, 125 mM CaCl 2 , and 20 ng of cDNA. Negative controls contained sterile H 2 O instead of cDNA, while positive controls were either Ls-WT, Ac-WT, or Ac-Y55W cDNA. Solutions were left to sit for 45+ minutes then added onto a monolayer of cells. Cells were then incubated for two days before expression of soluble protein was tested.
Stable cell-lines were generated using G418 (0.5mg/ml from Invitrogen) selection in HEK293S-GnT1 -cells. Cells in multilayer flasks were maintained in media with 2% fetal bovine serum. Protein expressed, using stable cell-lines, in media preserved with 0.02% NaN 3 was purified on an affinity column using anti-FLAG agarose beads (Sigma). Saturation of the column was checked using the scintillation proximity assay (SPA) quick screen described. Protein concentrations were determined via Bradford assay. The resolution quality of purification was checked via FPLC by running 10 μg of protein in filtered 50mM Tris-HCl pH 7.5, 140mM NaCl, and 0.02% NaN 3 over a Superose 6 10/300 GL column. Purifications showing peaks indicative of pentameric AChBP on the FPLC were used in further characterizations.
Generation of hα7-nAChR CNiFER cell lines in HEKtsA201 was performed as previously described (23) . In brief, TN-XXL gene (24) expression was introduced into HEKtsA201 hα7-nAChR stable cells via lentiviral transduction (25) and fluorescence activated cell sorted for high levels of eCFP and Citrine cp174 fluorescence.
Flex-Assay-Fluorescence detection of receptor activation was performed as previously described (23) . In brief, cells plated a day prior to the assay had the media replaced with 100µl of artificial cerebral spinal fluid (aCSF) containing 10 μM of the positive allosteric modulator (PAM) PNU-120596 (26), from Tocris, or antagonists at 1.5 times the final desired concentration in aCSF and PAM. Plates were incubated for at least 30 min at 37°C and 10% CO 2 , and run at 37°C on a Molecular Devices FlexStation III. Injection rates varied between 27-48 μl/s, and 50 µl of (±)-epibatidine at 3x final concentration was injected after 30 sec of baseline measurement. Reads of both donor eCFP (485 nm) and acceptor Citrine cp174 (527 nm) emission with eCFP excitation (436 nm) were made at 3.84 sec intervals. All wells were replicated (two or three times) in the same plate. Mean peak FRET ratios calculated from replicates, using SoftMax Pro 5.4 (Molecular Devices) were exported and plotted against agonist concentrations using GraphPad Prism 4. Net charge analysis (27) was not used since the PAM minimizes desensitization and responses do not necessarily return to baseline within the time-frame of our experiments. A sigmoidal concentration-response (variable slope) regression of the mean peak FRET ratios was fit to generate a concentration-response curve and obtain an EC 50 value.
To measure potencies of competitive antagonists, three concentration-response curves with different antagonist concentrations were compared to a control curve (without antagonist). Mean FRET responses were used to generate concentration-response curves, and antagonist dependent shifts in EC 50 values were used to calculate dose ratios (DR), as a concentration ratio of EC 50 '/EC 50 for the specified agonist (where EC 50 ' is in the presence of the antagonist at the specified concentration). K i values were calculated from the DR with K i = [Antagonist] / (DR-1) (28, 29) . The average K i generated from multiple antagonist concentrations per plate constituted an n of one.
All errors reported are arithmetic standard deviations unless otherwise noted.
Scintillation Proximity Assay (SPA)-Quick screen binding assays were performed using 100 µl of 0.2 mg/ml anti-mouse SPA AntibodyBinding Beads (Amersham Biosciences) mixed with 33.6 μg monoclonal anti-FLAG M2 antibody from mouse (Sigma) in 0.1 M NaPO 4 buffer, pH 7.0 (SPA cocktail). Media (5 µl), collected two days after transfection, was added to the cocktail and finally 10 µl of 3 H-(±)-epibatidine (Perkin Elmer) was added at a final concentration of 10 nM. Solutions were each counted for one minute on either a Beckman LS 6500 liquid scintillation counter or Wallac 1450 Microbeta Trilux.
Negative and positive controls consisted of media (5 µl) from the respective transfections.
Non-expressing mutants were transfected and verified de novo in triplicate. Western Immunoblots were also performed upon media (15 μl) from transfections to verify lack of expression.
Competition curves and direct binding were measured following the protocol previously described (30) . Concentrations of SPA bead and 3 H-(±)-epibatidine were optimized for noise/background ratios. Competing ligand was added at either half-log or 1/3-log dilutions. Briefly, AChBP (500 pM in binding sites) in SPA cocktail and 3 H-(±)-epibatidine (20 nM for Ac-AChBP, 5 nM for Ls-AChBP) were combined with increasing concentrations of the competing ligand.
Total and non-specific binding were determined in the absence and presence, respectively, of a saturating concentration (4 μM) of MLA. After background subtraction, data were fitted to a sigmoidal dose-response curve (variable slope), and K i values were calculated from the observed EC 50 values (31) using GraphPad Prism version 4.
Mutagenesis-Ls and Ac WT cDNAs were mutated using overlap extension PCR method (32) . Briefly, fragments were primed on either WT or mutated sequences to obtain desired mutations. PCR reactions were digested using HindIII/XbaI and then purified using an agarose gel and Qiagen Gel Extraction Kit. Digested inserts were ligated into a cut pFlag-CMV-3 (Sigma) vector. After transformation, each mutant sequence was purified using a Qiagen Miniprep Kit and sequenced using an ABI Sequencer or sent for sequencing (Retrogen).
A combinatorial cassette fashion of mutagenesis was used to obtain the first mutant AChBPs. The five sets are outlined in Figure  1A , and represented visually upon a structure in Figure 1B and C. Since set five extends set one, this yielded an initial 23 mutants for both Ac and Ls. Mutations were then extended based on expression studies to yield a total of 96 Ac and 28 Ls mutant cDNAs. Sequence alignments were produced using BioEdit.
Crystallography-Select mutants were screened against the Hampton Crystal Screen Cryo (HR2-122).
Solutions respectively. An initial model was generated using molecular replacement using a library of Ac-AChBP structures. Both CCP4i (33) and Phenix (34) were used to refine structures, while Coot (35, 36) was used to manipulate PDB structures in between refinements. Images were produced using both Coot and Pymol (37) Mutation sequences and structural overlay- Figure 1C shows an overlay of three ligands with preferences for association with α7-nAChRs: α-conotoxin ImI (α-Ctx ImI) (PDB ID: 2BYP, 18), DMXB-A (PDB ID: 2WNJ, 19) , and methyllycaconitine (MLA) (PDB ID: 2BYR, 18) used to identify candidate residues for mutation. These three ligands cover the largest contact surface area within the pocket. Homology modeling and crystal structure analysis were used to adjust gap placement in the sequence alignment between the three proteins ( Figure  1A ). We systematically mutated residues within 4Å of any of the respective ligands in any of the five binding pockets. The residues marked with solid triangles in the ligand binding domain were deemed to be critical ( Figure 1A ). Selected interactions are more prevalent than those previously described (18) , as not all pockets are necessarily synonymous. Initially the mutation sequence was conservative and kept to three residues per set, but each set was later extended to include a broader region. Mutated regions were chosen strategically in order to conserve predicted subunit interactions. These regions were systematically combined in case a lack of expression by one region could be potentially recovered by mutations in a neighboring region. Once the most extensive set of mutations possible was determined (a combination of mutation sets 2, 3, and 5 [Mutant I]), ligand selectivity was evaluated. In efforts to achieve hα7-nAChR properties, extended mutations were added to the first mutation sets (Mutant I), and a full structural and functional study was performed upon the selected final mutant (Mutant III).
Lymnaea stagnalis (Ls) and Aplysia californica (Ac) AChBPs were mutated as described in Methods in a combinatorial fashion of five initial sets.
Mutations were then extended based upon expression studies of the first 23 mutants. Supplementary Table 1 shows the results of the initial expression study where expression was determined by comparing cpm of bound ligand in media samples from transfected cDNA mutation sequences to a control transfection of AChBP-WT cDNA, using the SPA quick screen described. LsAChBP was amenable to mutations only in sets 1, 4, and 5 which are located in peripheral regions. The combination of these sets with any other mutations hindered expression leaving only 3 of 23 expressing mutant cDNAs; whereas, Ac-AChBP had 11 of 23 mutation sequences express. The only non-expressing region for Ac-AChBP was found in mutation set 4, the β8-9 linker and its inclusion in any combination.
Characterization of Ls-AChBP mutants-LsAChBP proved to be problematic in the core of the binding region and thus very few extended mutations were attempted. Supplementary Table 2 shows the results of a sixth set and the few extended mutation sequences created for LsAChBP. Only an extension of set 5 showed positive results, limiting our further studies. Thus our extended mutational efforts focused on Ac-AChBP.
Characterization of Ac-AChBP mutantsSince the β8-9 linker (F-loop) proved to be problematic for the Ac-AChBP, the mutation sequence containing all but that set, Mutant I, was chosen as the first intermediate mutant to test for binding activity. The described binding assays, as well as crystallographic studies, were carried out upon this intermediate (Mutant I).
Analyzing the initial binding characteristics described in Table 1 and Table 2 of the mutant showed that full conversion of binding characteristics towards the hα-nAChR, specifically among the larger antagonists, was not obtained from the smaller set of mutations in the binding pocket. Extended mutations were thus carried out on this mutated sequence to better replicate α7 selectivity. Crystallographic studies were performed to ensure that the 12 residue mutations of Mutant I did not hinder the structural determination of further mutants generated. An initial snapshot of the mutant was obtained at 3.0 Å (Supplementary Figure 1) . Extended mutations were made, and a total of 96 mutant cDNAs were generated. Expression results are shown in Supplementary Table 3 . Specific mutations of V53N, T91L, D77T, T76K, and mutated regions on the β8-9 linker proved to reduce expression greatly or eliminate it entirely. Although a sequence repeat of T 158 D 159 exists near the region of a two residue disparity, removal of one repeat did not yield robust expression, seen in Supplementary Table  3 .
The complementation of the mutation sequence of Mutant III with the removal of the T 158 D 159 repeat did however recover weak expression. This was our first observation of recovered expression by adding neighboring mutation sequences, yet this was not prevalent and only found in a few other β8-9 linker mutation sequences.
Ultimately, three extended mutants, Mutant II, Mutant III (both shown in Figure 1 , Supplementary Table 3) , as well as a third mutant (Mutant IV) that added Q162E, V163A, L165I, and S167G to Mutant III were chosen as further intermediates to test for hα7-nAChR selectivity. Since previous reports suggest that the β9-10 linker (C-loop) plays a defined role in ligand binding and gating (21, 38, 39) , we looked at Mutant II, which lacked mutation sets 5 and 1 of the β9-10 linker from Mutant III. Mutant IV proved unstable in yielding consistent binding characteristics and FPLC profiles (data not shown); therefore Mutant III was chosen as a final mutant of the mutated ligand binding domain. Although other regions of the β8-9 linker did express, the results of Mutant IV and the distance of those regions from the binding residues identified in Figure 1A deterred us from their characterization.
Mutant Stability-Mutant II yielded variable FPLC profiles, and it was determined that this mutant is cold sensitive (Figure 2A-D ), yet maintained a stable oligomeric structure at room temperature for 41 days ( Figure 2E and F) . Reversible equilibration between pentamer (25ºC) and the presumed monomer (4ºC), based on FPLC peak profiles of the mutant, was evident as long as protein concentrations remain high ( Figure 2C and D) .
Lowering the concentration, below 100μg/mL, resulted in an irreversible dissociation at both 4ºC and 25ºC, with dissociation at 4ºC occurring more rapidly (data not shown).
Mutant II was also irreversibly alkaline sensitive as shown in Supplementary Figure 2A , and slightly sensitive to acidic conditions Figure 3A . The addition of the β9-10 linker (mutation set 5 and extensions) increased stability whereby Mutant III is completely stable at 4ºC and therefore can be kept for significantly longer periods ( Figure 2G and H). Mutant III was also less sensitive to acidic conditions than Mutant II, but maintained a strong aversion to alkaline conditions ( Figure  3B and Supplementary Figure 2B) .
Binding characteristics and functional assays- Tables 1 and 2 show a comparison of the binding characteristics of Mutant II and III to Ac-AChBP as well as a comparison to both literature values of hα7-nAChR and the functional agonism and antagonism determined using the Flex assay described herein. Direct correlations of agonist affinities to the EC 50 values cannot be made as binding affinities are enhanced in the presence of PNU-120596 (26) . Therefore, we used the rank ordering of affinities in our assays, as well as literature values for activation of hα7-nAChR for comparisons. For agonists the rank ordering of Functional ordering may not match as a result of the use of PNU-120596. The β9-10 linker mutations (mutation set 5 with extensions) seem to reduce affinity for all agonists although to varying extents (compare Mutant II and III). Mutant I, containing some of the β9-10 linker mutations (mutation set 5) and lacking the central extended mutations, also seems to lose appreciable affinity for the agonists.
Antagonist elicited parallel shifts of (±)-epibatidine dose-response curves generated K i s from the functional assay of hα7-nAChR in cultured cells. The K i s generated from the dose ratios when compared to IC 50 s should better reflect the antagonist's affinity or receptor occupation. Antagonist values in Table 2 do not fully maintain the pattern of higher affinity for Mutant II as seen by only a small difference of α-bungarotoxin (α- ] show the largest increase in affinity to match those values of the hα7-nAChR, whereas α-Btx also significantly increases affinity but is still a hundred fold off of the hα7-nAChR values determined. However, the values determined for α-Btx did match those previously reported (60-70 nM) for an aggregating extracellular domain of hα7-nAChR (14) . (-)-Lobeline loses 10,000-fold affinity to more closely resemble that of hα7-nAChR with a five~ten fold affinity difference remaining. α-Ctx ImI shows a 100-fold reduction in affinity, but still has a ten-fold difference from our determined K i of hα7-nAChR. Although MLA has a lower affinity for Mutant III than for either hα7-nAChR or Ac-AChBP-WT, we see no change in binding pose from the crystal structures ( Figure 4) .
A non-competitive component can be seen for several antagonists in our functional assays. This may be attributed to slow dissociation rates relative to the time-frame of the assay, particularly manifested for (-)-lobeline and the peptidic antagonist α-Btx. (-)-Lobeline showed the strongest non-competitive component making it difficult to determine a K i as no significant signal was detected at concentrations above 16 μM.
Crystallographic analysis-Crystal structures were obtained for all three mutants. Mutant II and III were both crystallized with the antagonist MLA and diffracted to 2.3 Å and 2.9 Å, respectively (Table 3 shows the refinement statistics). Mutant I was crystallized with both (-)-nicotine and α-Btx. Both structures were of the same phasing and analysis showed no ligand (due presumably to the weak affinity of (-)-nicotine and the complexity of α-Btx) in either structure as well as similar overall poses, thus the Apo form of Mutant I was solved using the crystal formed from the (-)-nicotine solution.
Figures
Analysis of the pose of MLA in Mutant III is consistent with the expected hydrogen bond distance (19) between the protonated tertiary nitrogen on MLA and the backbone carbonyl oxygen of Trp 147 ( Figure 4A ). Although no significant overall conformational change is observed between Ac-AChBP WT and Mutant III, changes of residue side chain positions and space filling surface areas (Supplementary Figure 4) are seen with the most significant change between Ac-AChBP WT and Mutant III occurring in the position of Y55W ( Figure 4B ).
Upon substituting a larger charged residue with the Q186R mutation, Arg 186 adopts a more flexible state seen with the multiple conformations among subunits. The Q38L mutation yields fewer interactions with MLA and a larger gap space, potentially allowing for greater movement of the pyrrolidine-dione of MLA. This is consistent with the weaker densities seen in that region ( Figure 4B ).
The mutation sequence from Ac-AChBP to the hα7-nAChR sequence introduces a glycosylation site at position Asn 110 in both Mutants II and III. As a result of crystal packing, peripheral mannose residues of this oligosaccharide are visualized in one out of the five subunits in this GnT1-cell-line expressed protein ( Figure 5D ).
The interconnecting carbohydrates have significantly weaker density demonstrating the flexibility of the oligosaccharide that is stabilized peripherally by the symmetry mates of the peptide ( Figure 5D ). An overlay of α-Ctx-ImI with Mutant III shows potential points for polar interaction and with a few distances of 2.1 Å the potential for steric occlusion between the oligosaccharide and the ligand (Supplementary Figure 5) . The overlay demonstrates that the sugar may possibly interact with any ligand binding in the apical portion of the ligand binding pocket. We also find seven residues of the Cterminal segment, weakly defined, for AcAChBP in a conformation directed towards the ligand binding pocket of one out of the five subunits, presumably due to crystal packing in Mutant II (Supplementary Figure 6) .
A qualitative electrostatic analysis of the structures (excluding the oligosaccharide), while showing only a subtle overall difference, reveals a significant change in the ligand binding region shifting to a more negative dipole from WT to Mutant II on the complementary face. A clear difference between Mutant II and III can be visualized in the β9-10 linker of the primary face (Supplementary Figure 4) . Mass spectrometry of Mutant III in Supplementary Figure 7 verifies a predicted molecular weight with two glycosylation sites, although it shows that the mutant is found predominantly to contain a single oligosaccharide.
DISCUSSION
Comparison of Ls and Ac as templatesAlthough homologous in structure, the 32.3% difference in residue identity between the two mollusk AChBPs is clearly manifested in the initial expression results for the 23 mutations. The β8-9 linker (mutation set 4) does not express in Ac yet expresses in Ls even though Ls requires a three residue deletion to match hα7-nAChR. The core of the binding pocket near the pore (mutation set 2 and extended mutations) of the pentamer seems more amenable to mutations in Ac than Ls. This may result from a closer resemblance of Ac-AChBP to hα7-nAChR in this region of the binding pocket. Although the binding characteristics of Ls-AChBP better resemble those of hα7-nAChR (40) , the lack of the conserved Trp 55 in Ac-AChBP likely plays a significant role in differences. Ac-AChBP also differs in the location of the peripheral glycosylation site by a shift in six residues ( Figure 1A ). Recovering this area via mutation may confer subunit interactions towards those of hα7-nAChR.
Considering the extended mutations in AcAChBP, some of the mutations conferring low expression can be rationalized in terms of structure, while others defy a current explanation. Removal of the glycosylation site (T76K part of the consensus sequence N-I-T) and regions near it showed a weakening of expression. These side chains can be expected to reside at or very near the subunit interface. The T91L mutation is in another region that has close subunit interface contacts and may need more substantial regional mutations to accommodate a neighboring subunit. In both AChBPs the non-conserved residues are small (Thr/Ala in Ac or Ala/Ala in Ls) while hα7-nAChR contains two Leu. Some non-expressing mutants were quite surprising such as the β8-9 linker in Ac. Due to the flexibility of the β8-9 linker (41-43) one would consider this alteration to be more accommodating than those within the core of the pocket. The β8-9 linker does contain a two point deletion to achieve hα7-nAChR similarity and the neighboring beta-sheets were not fully swapped, thus the precise spatial correspondence of residues may have been disrupted by the mutations. Yet Ls-AChBP contains a three residue deletion and is quite amenable to the similar mutational change. The lack of mutations in the β8-9 linker may be a cause of the remaining difference of affinities for some of the larger ligands in Mutant III.
Overall binding correlation-A brief synopsis of differences in affinity between different animal species for α7-nAChR is shown in Supplementary Table 4 . Reported values for a common ligand and animal species occasionally may differ by approximately tenfold between laboratories. Five to ten-fold differences for the same ligand between animal species are also found. The Ac-AChBP β8-9 linker more closely resembles the rat nAChR than human for homologous residues within binding proximity (27) . Thus one can expect similar differences in a comparison of hα7-nAChR values to those of a soluble receptor surrogate.
A lack of complete correlation may also speak to the intrinsic quaternary structure that plays a role in ligand binding, reflecting the receptor's capacity to differentially occupy ligand in an activatable (resting), active (open channel) and desensitized states. Moreover, nAChRs are designed to equilibrate between these states, particularly in the presence of agonist, with distinct kinetic constants (44, 45) . By contrast the AChBPs may exist in only a single binding state. The absence of multiple binding states is consistent with the absence of cooperativity of binding of agonists in AChBP (46) , whereas most homomeric and heteromeric nicotinic receptors exhibit cooperativity for agonist occupation and functional responses. Subunit interactions with the receptor not only play a crucial role in defining the binding site, but also in facilitating the state change coupled with ligand binding. AChBP may only exist in a single bound state, perhaps most closely resembling the potential 'desensitized' form. This could explain the greater disparities in affinities of agonists versus antagonists between Mutant III and hα7-nAChR. Based on our findings, a soluble form of the hα7-nAChR extracellular domain would most likely also differ in ligand affinity characteristics from the full-length receptor.
A single binding state may be more conducive for achieving crystallization.
A single state of low and uniform free energy allows for tight interactions of the pentamer; whereas sequences promoting multiple states of near equivalent free energy, expected of an activatable receptor with desensitization capacity such as the hα7-nAChR, would require multiple alternative interactions. Accordingly, ligand binding is not governed simply by the immediate residues of the pocket interface, but rather intersubunit interactions attendant to conformational changes and cooperativity.
hα7-nAChR glycosylation-Although the putative glycosylation sites for hα7-nAChR have been identified, thus far the only thorough analysis of the role of glycosylation in ligand binding to hα7-nAChR has been with the glycosylation states affecting α-Btx binding. This α-neurotoxin binds to the β9-10 linker in the periphery of the ligand binding region and glycosylation of hα7-nAChR has no effect upon its binding (47) . Yet the generation of the stable mutant AChBPs presented here has revealed the location and extent of glycosylation of the extracellular domain of hα7-nAChR to be within the vicinity of ligand binding for those ligands that bind in the apical region of the pocket. In our case the oligosaccharide did not interact with MLA, but rather was pulled away from the binding side by symmetry mates ( Figure 5D ). Additionally all of the binding studies presented were performed upon a Gnt1-variant of HEK293S cells such that the oligosaccharide is homogeneous and only present in the high mannose form. The creation of the reported mutants will now allow for an in-depth characterization of the role of glycosylation in hα7-nAChR ligand binding.
Structural analysis-The overall backbone alignment of Ac-AChBP and Mutant III showed no significant change as has been already discussed, but the mutation sequences do alter the binding site volume found in the ligand binding region. Not only is there a change in the electrostatic potential of the protein's surface from the incorporated mutations, but there are changes to the surface of binding space available to ligands (especially with the incorporation of a novel glycosylation site) shown in Supplementary Figures 3,4 , and 5. We have aligned all represented subunits and/or pentamers, rather than a single simplified subunit view, in Figures 4B, 5A , and 5B as well as Supplementary Figures 3 and 5 to demonstrate the heterogeneity found in a single crystal structure. Although an overall static pose, the conformational variations of residues and oligosaccharides adopted between subunits via various crystal packing offers a glimpse into the flexibility of the those regions. Another aspect that could potentially increase crystal structure resolution and potentially alter ligand specificity is the removal of the long flexible Cterminal region of the Ac-AChBP. The weak visualization of the C-terminal approaching the ligand pocket, and the expression of a truncated variant A209* (Supplementary Table 3) suggest that future experiments of Ac-AChBP or any variant be performed upon a truncated form.
Conclusions-We present here a systematic generation, through successive reiterations, of a mutant AChBP that resembles the properties of the native hα7-nAChR. This results in a marked improvement of ligand affinity correlation to hα7-nAChR from the WT Ac-AChBP to Mutant III, especially for the larger antagonists. Yet the lack of perfect correlation of Mutant III speaks to the intrinsic role that peripheral residue interactions, in both the principle and adjoining subunits, play in shaping the ligand binding domain. The stability of the mutant sequences generated allows us to speculate that our success, albeit limited, may be repeated with other variants of the nAChR family to produce a "homomeric" ligand binding region resembling heteromeric receptors of interest such as α4β2. 3SIO) showed definition of C-terminal in two out of ten subunits due to crystal packing arrangement. Alignment of the two pentamers (cyan and blue) with the two subunits is shown above. 2Fo-Fc electron density of the terminal chain is shown at 1σ in cyan while a composite OMIT map (also at 1σ) is shown in magenta both for the cyan subunit. The C-terminal bends up and in towards the binding pocket with a loss of density 8 Å away from the pyrrolidine of MLA. The remaining five residues of the C-terminal are not visualized in the structure.
SUPPLEMENTARY FIGURE 7:
Mass Spectrometry Analysis of Mutant III. MALDI-TOF profile of Mutant III acquired using a DE-STR MALDI-TOF mass spectrometer. Arrows point to the peaks of the monomer, dimer, trimer, tetramer, and pentamer. Inset shows a magnification of the monomeric peak. Two variations, a singly glycosylated and doubly glycosylated form are visible with the singly glycosylated form as the predominant species having a shoulder peak resulting from either incomplete glycosylation or ragged ends (94) . The calculated theoretical mass of Mutant III is 26296.68 with 1219.83 added for each high-mannose.
